# US Carotid Artery Disease Market

> US Carotid Artery Disease Market Research Report: By Diagnosis & Treatment (Carotid Artery Disease, Antihypertensive Drugs) and By End User (Hospital & Clinics, Ambulatory Surgical Centers, Pharmacies) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.7%
- **2024:** $ 2,630 Million
- **2025:** $ 2,753.61 Million
- **2035:** $ 4,360 Million
- **Key Players:** Medtronic (US), Abbott Laboratories (US), Boston Scientific (US), Johnson & Johnson (US), B. Braun Melsungen AG (DE), Terumo Corporation (JP), Stryker Corporation (US), Cook Medical (US), Cardinal Health (US)

**Report ID:** MRFR/MED/11607-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** May 13, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-carotid-artery-disease-market-13132

---

## Market Summary

## **US Carotid Artery Disease Market Overview**

As per MRFR analysis, the US Carotid Artery Disease Market Size was estimated at 2.5 (USD Billion) in 2023. The US Carotid Artery Disease Market Industry is expected to grow from 2.8(USD Billion) in 2024 to 4.8 (USD Billion) by 2035. The US Carotid Artery Disease Market CAGR (growth rate) is expected to be around 5.022% during the forecast period (2025 - 2035).

### **Key Market Trends of US Carotid Artery Disease Market**

Recent trends in the US Carotid Artery Disease Market indicate a growing emphasis on preventive care and early diagnosis. With the increasing prevalence of factors such as obesity and diabetes, there is heightened awareness among healthcare providers and patients about the risks associated with carotid artery disease. Routine screening technologies, including ultrasound and advanced imaging techniques, are increasingly being adopted in clinical practice, promoting early detection and improved outcomes for patients.

Additionally, there's a rising focus on minimally invasive treatment options, which are more appealing to patients due to shorter recovery times and lower procedural risks. This shift reflects a broader trend towards patient-centered care in the US healthcare landscape. Key market drivers include an aging population, as older adults are more susceptible to [carotid artery disease](../../../reports/carotid-artery-disease-market-6301). The US Census Bureau projects that the number of elderly individuals will continue to increase, further stressing the need for effective diagnosis and treatment solutions.

Moreover, advancements in medical technology are facilitating the development of innovative products and therapies for managing carotid artery disease, driving investment and research in this field. Opportunities in the US market can be explored through the integration of digital health solutions, such as telemedicine and mobile health applications, which can enhance patient engagement and monitoring. As healthcare providers seek to improve care delivery, there is potential for collaborations between technology companies and healthcare institutions to develop solutions that streamline disease management.

Overall, the US Carotid Artery Disease Market is evolving with a strong focus on innovation and holistic patient care, positioning itself to address the growing needs of the population effectively.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Carotid Artery Disease Market Drivers**

### **Aging Population in the United States**

The aging population in the United States is a significant driver for the US Carotid Artery Disease Market Industry. According to the U.S. Census Bureau, the number of adults aged 65 and older will increase from 56 million in 2020 to approximately 94 million by 2060. This demographic shift is particularly concerning since carotid artery disease is often associated with older adults due to the accumulation of risk factors such as hypertension and atherosclerosis.

Organizations like the American Heart Association actively focus on promoting awareness and screening among older populations, which is expected to result in a higher demand for treatments and surgical interventions related to carotid artery disease. As a result, the increasing number of older adults will likely enhance market growth, leading to a fostered need for innovative therapies and surveillance mechanisms.

### **Rising Incidence of Risk Factors**

The rising incidence of risk factors such as obesity, hypertension, and diabetes is poised to drive significant growth in the US Carotid Artery Disease Market Industry. Data from the Centers for Disease Control and Prevention (CDC) indicates that the prevalence of obesity has significantly increased, with more than 42% of adults classified as obese in 2018. Additionally, about 34 million Americans have diabetes, which is a key risk factor for carotid artery disease.

As healthcare organizations recognize these alarming statistics, there is a push toward preventive measures including lifestyle modification programs and enhanced screening protocols. Such initiatives are anticipated to increase awareness and diagnosis of carotid artery disease, ultimately resulting in a higher demand for medical interventions.

### **Advancements in Medical Technology**

Technological advancements in medical devices and surgical procedures are substantially driving the US Carotid Artery Disease Market Industry. Innovations such as minimally invasive endovascular techniques and improved imaging technology have made it easier for healthcare professionals to diagnose and treat carotid artery disease effectively. For instance, developments in stent technology and balloon angioplasty have shown to improve patient outcomes significantly.

The Food and Drug Administration (FDA) continues to approve new technologies that provide safer options for patients, which encourages healthcare providers to adopt these advanced solutions. This uptake is crucial as hospitals and clinics prioritize patient-centered care, promoting a more competitive market landscape aimed at enhancing treatment outcomes for carotid artery disease.

### **Increasing Healthcare Expenditure**

The increase in healthcare expenditure for cardiovascular diseases in the United States serves as a vital driver for the US Carotid Artery Disease Market Industry. According to the American College of Cardiology, total healthcare spending on cardiovascular diseases reached approximately 219 billion USD in 2017, with carotid artery disease representing a significant portion of this expenditure. The increased allocation of resources towards cardiovascular care indicates a stronger commitment from both private and public sectors to address conditions like carotid artery disease.

As healthcare providers enhance access to preventive screenings and therapeutic options, the market for carotid artery disease treatments is projected to expand. This reinforces the importance of prioritizing cardiovascular health as a key area of focus within the broader healthcare ecosystem in the United States.

## **US Carotid Artery Disease Market Segment Insights**

### **Carotid Artery Disease Market Diagnosis & Treatment Insights**

The Diagnosis and Treatment segment of the US Carotid Artery Disease Market is pivotal in addressing the growing health concerns related to carotid artery diseases, a condition that can lead to severe cardiovascular events such as strokes. With medical advancements and the increased prevalence of hypertension and related conditions, this segment has gained prominence in recent years. The rise in the aging population in the United States, known to be at higher risk for carotid artery disease, contributes to the need for effective diagnostic tools and treatment options, thereby driving the market growth.

Currently, multiple methodologies are employed in the diagnosis of carotid artery diseases, including imaging tests such as ultrasound, CT scans, and MRIs. These diagnostic approaches enable healthcare providers to determine the extent of arterial blockage and formulate appropriate treatment plans efficiently. Among the treatment options available, antihypertensive drugs play a crucial role as they help in managing blood pressure levels, substantially reducing the risk of stroke and other related complications in patients with carotid artery disease.

Although there is a vast array of medications, the market dynamics are influenced by advancements in pharmacotherapy, leading to higher efficacy and better patient compliance.

Furthermore, there is a continued emphasis on patient education as a component of treatment, ensuring that individuals are well informed about risk factors, lifestyle modifications, and adherence to prescribed therapies. The healthcare system in the US is gradually shifting towards value-based care, emphasizing better patient outcomes through evidence-based practices, which has a direct impact on treatment approaches in this segment. Nevertheless, challenges such as high healthcare costs and varying access to advanced treatment modalities persist. Moreover, regulatory pathways for new drugs and therapeutic devices can often be complex and lengthy.

As healthcare professionals strive to innovate and enhance patient outcomes, opportunities arise for new drug formulations and advanced diagnostic technologies to capture significant market share. This segment is expected to continue to flourish, driven by technological advancements and a growing understanding of the critical nature of timely diagnosis and comprehensive management of carotid artery disease. The underlying factors influencing the segment’s dynamics, such as patient-centered care models and the incorporation of telehealth services, highlight the continual evolution within the Diagnosis and Treatment segment of the US Carotid Artery Disease Market.

The integration of these factors illustrates the industry's commitment to not only treating existing conditions but also preventing further morbidity and enhancing the quality of life for patients at risk.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Carotid Artery Disease Market End User Insights**

The US Carotid Artery Disease Market, particularly focusing on the End User segment, comprises key areas such as Hospitals, Clinics, Ambulatory Surgical Centers, and Pharmacies. Hospitals and Clinics play a pivotal role, providing comprehensive diagnosis and treatment for carotid artery disease, leading to a trend of increasing patient visits for vascular-related issues. Ambulatory Surgical Centers have gained traction due to their ability to offer cost-effective and less invasive options for patients, often attracting a larger share of the outpatient market.

Pharmacies also contribute significantly, serving as accessible points for medication management and patient education on carotid health. These establishments are essential as they cater to the growing awareness and demand for efficient healthcare solutions, driven by a rise in cardiovascular diseases across the US. The integration of advanced technologies and the emphasis on patient-centered care further boost their importance and effectiveness in managing carotid artery disease, streamlining treatment processes and enhancing patient outcomes.

As the landscape of healthcare continues to evolve, these end-user frameworks remain integral to the overall efficacy of the US Carotid Artery Disease Market, adapting to trends while aligning with patient needs for better health management.

## **US Carotid Artery Disease Market Key Players and Competitive Insights**

The US Carotid Artery Disease Market is an evolving landscape characterized by various innovative solutions tailored to address the complexities of carotid artery diseases, which are significant contributors to stroke and other cardiovascular afflictions. The market demonstrates a competitive fabric woven from the presence of established players and emerging entities that continually strive to enhance treatment outcomes through advancements in technology, product efficacy, and patient care strategies. Companies in this sector are focusing on diversifying their product offerings, increasing their R&D investments, and forming strategic partnerships to gain a competitive edge and bolster their market presence.

Regulatory approvals and compliance also play a crucial role in determining the success of products in this market as they directly affect the companies' ability to provide safe and effective treatments to patients.

### **Bard Peripheral Vascular**

Bard Peripheral Vascular enjoys a strong foothold in the US Carotid Artery Disease Market, attributed to its robust portfolio of vascular intervention devices and extensive experience in the field. The company's strategic focus on the development of innovative products that improve patient outcomes enhances its reputation among healthcare professionals and patients alike. Bard Peripheral Vascular's strength lies in its comprehensive understanding of vascular access and intervention, coupled with a commitment to education and training for healthcare practitioners. This enables them to stay at the forefront of technological advancements and market demands within the US region.

Their established distribution networks and relationships with major healthcare facilities further leverage their market presence, leading to a sustained competitive advantage.

### **Microvention**

Microvention is another key player in the US Carotid Artery Disease Market, renowned for its innovative neurovascular devices and commitment to advancing treatment for vascular disorders. The company’s notable product range includes advanced stent systems and embolic protection devices aimed at improving treatment efficacy and reducing procedural risks related to carotid artery disease. Microvention's strategic partnerships and collaborations with leading medical institutions in the US bolster its product development efforts and market strategies. Furthermore, its active engagement in clinical trials highlights its dedication to evidence-based practice and ongoing innovation.

The company's focus on acquiring cutting-edge technology and integrating new capabilities through mergers and acquisitions facilitates its growth and competitive positioning in the market. Overall, Microvention leverages its expertise and innovative product pipeline to enhance patient care and improve its market standing in the US Carotid Artery Disease Sector.

### **Key Companies include in US Carotid Artery Disease Market**

- Bard Peripheral Vascular
- Microvention
- Endologix
- Terumo Corporation
- NeuroVasc Technologies
- Medtronic
- Abbott Laboratories
- Boston Scientific
- Cerenovus
- Stryker Corporation
- Penumbra
- Vascular Solutions
- AngioDynamics
- Johnson and Johnson

## **US Carotid Artery Disease Market Industry Developments**

Recent developments in the US Carotid Artery Disease Market have been significant, particularly with advancements in medical devices and treatment methodologies. For instance, Bard Peripheral Vascular continues to innovate with new stenting options aimed at enhancing patient outcomes. Medtronic has reported positive growth following the launch of its latest carotid interventions, reflecting increased demand and improving technologies. In terms of mergers and acquisitions, AngioDynamics announced the acquisition of a smaller device manufacturer in March 2023, aimed at expanding their vascular product line. Meanwhile, Boston Scientific has engaged in strategic partnerships to enhance its market presence for carotid artery products.

The overall market has seen a valuation growth driven by rising incidences of carotid artery disease, with estimates indicating a compound annual growth rate (CAGR) of over 5% through the upcoming years. Additionally, Johnson and Johnson has invested heavily in Research and Development to advance less invasive treatment options, responding to the growing need for effective carotid disease management. Notable regulatory approvals have also been granted to several new therapies, thereby enhancing treatment accessibility for patients across the United States.

## **US Carotid Artery Disease Market Segmentation Insights**

### **Carotid Artery Disease Market Diagnosis & Treatment Outlook**

- Carotid Artery Disease
- Antihypertensive Drugs

### **Carotid Artery Disease Market End User Outlook**

- Hospital & Clinics
- Ambulatory Surgical Centers
- Pharmacies

## Market Drivers

### Increased Focus on Preventive Healthcare

The shift towards preventive healthcare is influencing the carotid artery-disease market. As awareness of cardiovascular health rises, more individuals are seeking regular screenings and preventive measures. Initiatives by health organizations and government agencies promote lifestyle modifications and early detection of risk factors associated with carotid artery disease. This trend is reflected in the growing market for preventive services, which is expected to expand at a rate of approximately 5% annually. Consequently, the emphasis on prevention is likely to drive demand for diagnostic tools and treatment options within the carotid artery-disease market.

### Rising Incidence of Carotid Artery Disease

The increasing prevalence of carotid artery disease in the US is a primary driver for the carotid artery-disease market. Factors such as an aging population, lifestyle choices, and comorbidities like hypertension and diabetes contribute to this rise. According to the CDC, approximately 18 million adults in the US have coronary artery disease, which often correlates with carotid artery issues. This growing patient population necessitates enhanced diagnostic and therapeutic options, thereby expanding the market. As healthcare providers focus on early detection and management, the demand for innovative treatments and interventions is likely to surge, further propelling the carotid artery-disease market.

### Advancements in Medical Imaging Technologies

Innovations in medical imaging technologies are significantly impacting the carotid artery-disease market. Enhanced imaging modalities, such as high-resolution ultrasound, CT angiography, and MRI, allow for more accurate diagnosis and assessment of carotid artery conditions. These advancements facilitate timely interventions, which are crucial for preventing strokes and other complications. The market for imaging technologies is projected to grow, with estimates suggesting a CAGR of around 6% over the next few years. As healthcare providers increasingly adopt these technologies, the carotid artery-disease market is expected to benefit from improved patient outcomes and increased procedural volumes.

### Growing Investment in Healthcare Infrastructure

The expansion of healthcare infrastructure in the US is a significant driver for the carotid artery-disease market. Increased funding for hospitals and outpatient facilities enhances the availability of advanced diagnostic and treatment options. The US government has allocated substantial resources to improve healthcare access, particularly in underserved areas. This investment is likely to lead to a rise in the number of procedures performed for carotid artery disease, thereby boosting market growth. Furthermore, the establishment of specialized centers for vascular health may enhance patient care and outcomes, further stimulating the carotid artery-disease market.

### Emerging Biologics and Pharmacological Treatments

The development of new biologics and pharmacological treatments is reshaping the carotid artery-disease market. Innovative therapies targeting inflammation and plaque stabilization are gaining traction, offering potential alternatives to traditional surgical interventions. The market for these advanced treatments is projected to grow significantly, with estimates indicating a potential increase of 8% in the next few years. As clinical trials yield promising results, healthcare providers may increasingly adopt these therapies, thereby enhancing patient management strategies in the carotid artery-disease market.

## Future Outlook

The [Carotid Artery Disease Market](https://www.marketresearchfuture.com/reports/carotid-artery-disease-market-6301) is projected to grow at a 4.7% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence, and enhanced healthcare access.

**New opportunities:**

- Development of AI-driven diagnostic tools for early detection Expansion of telehealth services for remote patient monitoring Investment in minimally invasive surgical technologies for improved outcomes

By 2035, the market is expected to achieve robust growth, reflecting advancements and increased demand.

## Segment Insights

### By Type: Surgery (Largest) vs. Medication (Fastest-Growing)

In the US carotid artery-disease market, the primary segment is Surgery, which holds the largest market share. This segment benefits from established practices and high demand for surgical interventions, as they provide immediate solutions for severe cases. Medication follows as a significant player, gaining traction due to advancements in pharmacotherapy and the increasing prevalence of carotid artery disease, thereby contributing to the overall market landscape. The growth trends in this segment indicate a strong shift towards Medication as the fastest-growing area, propelled by innovative drug therapies and rising awareness of preventative care. Factors such as an aging population, increased diagnostics, and evolving clinical guidelines are contributing to the expansion of both Surgery and Medication segments, with Medication rapidly adapting to the needs of patients seeking less invasive options.

Surgery (Dominant) vs. Medication (Emerging)

Surgery remains the dominant segment in the US carotid artery-disease market, characterized by traditional approaches such as carotid endarterectomy and stenting. These methods provide reliable solutions for high-risk patients and are commonly recommended by healthcare professionals. On the other hand, Medication is emerging as a vital segment driven by the development of new drugs aimed at managing symptoms and preventing disease progression. This segment's growth is fueled by the increasing preference for non-invasive therapies, enhanced drug efficacy, and the shift towards personalized medicine, ultimately making it a transformative force in the overall market.

### By Diagnosis: Duplex Ultrasound (Largest) vs. Compound Tomography (Fastest-Growing)

In the US carotid artery-disease market, Duplex Ultrasound is recognized as the largest segment, commanding significant market share due to its non-invasive nature and widespread availability. At the same time, Compound Tomography is emerging as a strong contender, particularly in specialized diagnostics, drawing interest for its precision and enhanced imaging capabilities. Maintaining a competitive edge, both segment values are pivotal in providing comprehensive diagnostic solutions. Growth trends in this segment are being accelerated by advancements in imaging technology and an increasing emphasis on early diagnosis of carotid artery diseases. The rising prevalence of cardiovascular disorders, fueled by lifestyle changes and an aging population, is driving demand for effective diagnostic methods. As healthcare providers seek more efficient instruments, the focus remains on integrating innovative technologies to enhance patient outcomes and streamline workflow processes.

Duplex Ultrasound (Dominant) vs. Compound Tomography (Emerging)

Duplex Ultrasound serves as the dominant modality in the diagnosis of carotid artery diseases, known for its cost-effectiveness and proficiency in evaluating blood flow, making it the preferred choice among clinicians. Its ability to provide immediate results without requiring patient hospitalization further solidifies its position. In contrast, Compound Tomography is an emerging technology that combines high-resolution imaging with advanced software analysis, which makes it particularly appealing for intricate cases where detailed vascular visualization is paramount. As both technologies continue to evolve, they cater to different aspects of patient care; Duplex Ultrasound excels in routine assessments while Compound Tomography is increasingly sought after for complex diagnostic scenarios.

### By Medications: Antiplatelet Drugs (Largest) vs. Cholesterol-Lowering Statins (Fastest-Growing)

In the US carotid artery-disease market, the medications segment is prominently led by antiplatelet drugs, which hold a significant market share due to their established efficacy in preventing thrombotic events. Cholesterol-lowering statins follow but are quickly gaining traction among physicians and patients alike, reflecting a shift towards proactive management of cholesterol levels in at-risk populations. The growth dynamics within this segment are influenced by rising awareness regarding cardiovascular health and the increasing prevalence of carotid artery diseases. Antihypertensive drugs are also seeing expanded utilization as hypertension becomes a more recognized risk factor. The overall drive towards personalized medicine is likely to boost the market further, as patients seek tailored therapeutic solutions that address their unique health profiles.

Antiplatelet Drugs (Dominant) vs. Cholesterol-Lowering Statins (Emerging)

Antiplatelet drugs remain the dominant force in the medications segment of the US carotid artery-disease market, primarily due to their indispensable role in managing and mitigating the risks associated with clot formation. These drugs, widely prescribed, exhibit robust clinical backing and long-term use history. In contrast, cholesterol-lowering statins are emerging as crucial in this space, reflecting a growing understanding of the link between cholesterol levels and cardiovascular health. Their increasing adoption is driven by an expanding body of research supporting their use in primary prevention. This dynamic portrays a landscape where traditional therapies coexist with newer approaches emphasizing preventive care.

### By Surgical Procedures: Carotid Endarterectomy (Largest) vs. Carotid Angioplasty (Fastest-Growing)

In the US carotid artery-disease market, Carotid Endarterectomy holds the largest market share, reflecting its established status as a primary treatment method for severe carotid artery stenosis. In contrast, Carotid Angioplasty, although currently a smaller segment, is experiencing significant uptake, particularly among patients seeking less invasive options. This shift is driven by the growing preference for innovative and minimally invasive surgical techniques that allow for quicker recovery and less hospital time. The growth trends within this segment are influenced by several factors, including advancements in catheter technology, increased awareness of carotid artery disease, and an aging population. This demographic shift has led to a higher prevalence of carotid artery diseases, thereby amplifying the demand for effective surgical interventions. Furthermore, ongoing research and clinical studies supporting the efficacy of these procedures are anticipated to further stimulate growth in the segment.

Carotid Endarterectomy (Dominant) vs. Carotid Angioplasty (Emerging)

Carotid Endarterectomy (CEA) is recognized as the dominant procedure in the US carotid artery-disease market due to its proven effectiveness in preventing strokes. This surgical intervention involves the removal of atherosclerotic plaque from the carotid arteries and has established itself as the standard of care for certain patient populations, especially those with severe carotid artery narrowing. Conversely, Carotid Angioplasty, which utilizes a balloon catheter to widen the artery, is emerging as a less invasive alternative, appealing particularly to patients concerned about the recovery time and procedural risks associated with traditional surgeries. As technological innovations continue to enhance the safety and effectiveness of angioplasty, its growth potential looks promising, particularly among younger patients who favor minimally invasive options.

### By End-User: Clinics (Largest) vs. Ambulatory Surgical Centres (Fastest-Growing)

In the US carotid artery-disease market, the end-user segment is primarily distributed among clinics and hospitals, pharmacies, and ambulatory surgical centres. Clinics stand out as the largest segment, leveraging their extensive patient base and established trust. Meanwhile, pharmacies are vital for post-operative care and medication management, although they hold a smaller share compared to clinics and hospitals. Ambulatory surgical centres are emerging rapidly as a significant player, reflecting the evolving landscape of healthcare delivery. Growth trends in the end-user segment are driven by several factors, including the increasing prevalence of carotid artery diseases and the shift towards more outpatient services. Patients are increasingly seeking minimally invasive treatments often available in ambulatory surgical centres, which are becoming the fastest-growing segment. Furthermore, advancements in medical technology and an emphasis on cost-effective treatment options are reinforcing the prominence of clinics in this market, ensuring that patient care remains at the forefront of their services.

Clinics (Dominant) vs. Ambulatory Surgical Centres (Emerging)

Clinics dominate the end-user segment in the US carotid artery-disease market due to their pivotal role in diagnosing and managing a wide range of carotid conditions. Their established infrastructure and personalized patient care foster strong patient relationships, contributing to higher patient volumes. In contrast, ambulatory surgical centres are emerging due to their focus on providing specialized surgical interventions with reduced recovery times and costs. This shift caters to the demand for more convenient and efficient care, positioning them as a viable alternative to traditional hospital settings. Consequently, ambulatory surgical centres are gaining popularity, especially among patients looking for timely and effective treatment options.

## Competitive Benchmarking

The carotid artery-disease market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Medtronic (US), Abbott Laboratories (US), and Boston Scientific (US) are at the forefront, leveraging their extensive research and development capabilities to introduce advanced therapeutic options. Medtronic (US), for instance, has positioned itself as a leader in minimally invasive technologies, which aligns with the growing demand for less invasive treatment options. Meanwhile, Abbott Laboratories (US) emphasizes its commitment to digital health solutions, integrating technology into its product offerings to enhance patient outcomes. This collective focus on innovation and technology is reshaping the competitive dynamics of the market, fostering an environment where companies must continuously adapt to meet evolving healthcare needs.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency and reduce costs. The market appears moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. This competitive structure allows for a diverse range of products and services, catering to various patient needs while also driving innovation through competition.
In October Boston Scientific (US) announced the launch of its new carotid artery stent system, which incorporates advanced materials designed to improve patient outcomes. This strategic move not only enhances the company’s product portfolio but also positions it to capture a larger share of the market by addressing the specific needs of patients undergoing carotid interventions. The introduction of this technology reflects a broader trend towards personalized medicine, where treatments are tailored to individual patient profiles.
In September Abbott Laboratories (US) expanded its partnership with a leading telehealth provider to integrate remote monitoring capabilities into its carotid artery disease management solutions. This collaboration is significant as it aligns with the increasing demand for telehealth services, particularly in chronic disease management. By enhancing its offerings with digital health solutions, Abbott Laboratories (US) is likely to improve patient engagement and adherence, ultimately leading to better health outcomes.
In August Medtronic (US) entered into a strategic alliance with a prominent research institution to develop next-generation imaging technologies for carotid artery disease diagnosis. This partnership underscores the importance of innovation in the market, as it aims to enhance diagnostic accuracy and treatment planning. Such collaborations are indicative of a trend where companies are investing in research and development to stay ahead in a competitive landscape.
As of November the carotid artery-disease market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence (AI) into healthcare solutions. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological advancements, innovative treatment options, and reliable supply chains. This shift may ultimately lead to improved patient outcomes and a more sustainable healthcare ecosystem.

## Recent News & Developments

Recent developments in the US Carotid Artery Disease Market have been significant, particularly with advancements in medical devices and treatment methodologies. For instance, Bard Peripheral Vascular continues to innovate with new stenting options aimed at enhancing patient outcomes. Medtronic has reported positive growth following the launch of its latest carotid interventions, reflecting increased demand and improving technologies. In terms of mergers and acquisitions, AngioDynamics announced the acquisition of a smaller device manufacturer in March 2023, aimed at expanding their vascular product line. Meanwhile, Boston Scientific has engaged in strategic partnerships to enhance its market presence for carotid artery products.

The overall market has seen a valuation growth driven by rising incidences of carotid artery disease, with estimates indicating a compound annual growth rate (CAGR) of over 5% through the upcoming years. Additionally, Johnson and Johnson has invested heavily in Research and Development to advance less invasive treatment options, responding to the growing need for effective carotid disease management. Notable regulatory approvals have also been granted to several new therapies, thereby enhancing treatment accessibility for patients across the United States.

## Report Scope

| MARKET SIZE 2024 | 2630.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2753.61(USD Million) |
| MARKET SIZE 2035 | 4360.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.7% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Medtronic (US), Abbott Laboratories (US), Boston Scientific (US), Johnson & Johnson (US), B. Braun Melsungen AG (DE), Terumo Corporation (JP), Stryker Corporation (US), Cook Medical (US), Cardinal Health (US) |
| Segments Covered | Type, Diagnosis, Medications, Surgical Procedures, End-User |
| Key Market Opportunities | Advancements in minimally invasive procedures enhance treatment options in the carotid artery-disease market. |
| Key Market Dynamics | Technological advancements in minimally invasive procedures are reshaping treatment options in the carotid artery-disease market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US carotid artery-disease market?**
A: The market valuation was $2630.0 Million in 2024.

**Q: What is the projected market size for the US carotid artery-disease market by 2035?**
A: The market is expected to reach $4360.0 Million by 2035.

**Q: What is the expected CAGR for the US carotid artery-disease market during the forecast period 2025 - 2035?**
A: The expected CAGR is 4.7% during the forecast period.

**Q: Which companies are the key players in the US carotid artery-disease market?**
A: Key players include Medtronic, Abbott Laboratories, Boston Scientific, and Johnson & Johnson.

**Q: What are the main segments of the US carotid artery-disease market?**
A: The main segments include Type, Diagnosis, Medications, Surgical Procedures, and End-User.

**Q: What was the valuation of the surgical procedures segment in 2024?**
A: The surgical procedures segment was valued at $2630.0 Million in 2024.

**Q: How much is the medication segment projected to be worth by 2035?**
A: The medication segment is projected to be worth between $1200.0 Million and $1800.0 Million by 2035.

**Q: What is the valuation range for duplex ultrasound in the diagnosis segment?**
A: The valuation range for duplex ultrasound is between $790.0 Million and $1300.0 Million.

**Q: What are the expected valuations for the end-user segment in 2025?**
A: The end-user segment is expected to range from $780.0 Million to $1750.0 Million.

**Q: Which surgical procedure segment has the highest valuation in 2024?**
A: Carotid endarterectomy had the highest valuation at $1630.0 Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-carotid-artery-disease-market-13132*